logo
Thousands Of Microplastics Floating In Your Home And Car Are Slowly Damaging Your Lungs: Study

Thousands Of Microplastics Floating In Your Home And Car Are Slowly Damaging Your Lungs: Study

Forbes6 days ago
While we live in the Plastics Age, and it may no longer be a huge surprise that we are constantly exposed to microplastics, a new study claims that we might be inhaling 100 times more microplastics in our own homes and cars than scientists had previously estimated. To be more specific, human beings might be inhaling around 68,000 microplastic particles that are not visible to the naked eye inside their homes and cars.
Lead author Nadiia Yakovenko and team from the Université de Toulouse in France had collected 16 air samples from their apartments and cars. The researchers then measured the concentrations of microplastics present in each air sample, as well as the size of the microplastics. They particularly focused on microplastics that are less than 10 micrometers and more likely to penetrate deep into lung tissues compared to fine particulate matter that is bigger than 10 micrometers or visible to the naked eye. Studies have found that inhaled particles larger than 10 µm are more likely to get collected in the upper respiratory tract and automatically get cleared out of your airways. However, your respiratory system cannot filter out fine particulate matter smaller than 10 micrometers, and so, it can penetrate deeper into the lungs. Microplastics smaller than 10 micrometers are of particular concern because they could release toxic additives into your cardiovascular system along with other environmental pollutants that it might have absorbed while floating around in the air.
Multiple studies have shown that microplastics could potentially disrupt your body's normal endocrine functions and might even increase the risk of various diseases like cancer.
"Microplastic is a ubiquitous pollutant resulting from the global extensive human use of plastic materials since 1950 and the mismanagement of plastic waste. The term 'microplastic' refers to plastic particles between 1 µm and 5mm in size that come in a variety of shapes and polymer compositions," the authors explained in their study that was published in PLoS One on July 30. "Human inhalation of fine particulate microplastic 1–10 µm that penetrate deep lung tissue may contribute to causing lung tissue damage, inflammation, and associated diseases."
"Over the past decade, microplastics have been detected in outdoor atmospheric aerosols and deposition, in various parts of the world, from urban and highly industrialized areas to remote mountainous regions, the marine boundary layer, and indoor environments. The ubiquitous presence of microplastics in the atmosphere raises many concerns about whether, and to what extent, we are inhaling microplastics from outdoor and indoor air, with the latter likely playing the most significant role in human exposure to microplastics through inhalation," they added. 'Recent studies have shown that the concentration of indoor suspended MPs is eight times higher than outdoors, and the concentration of indoor deposited microplastic dust is 30 times higher than outdoors. Given that people in developed nations spend approximately 90% of their time indoors, including 5% in cars, the potential for inhalation exposure to MPs in indoor environments is significantly higher and warrants attention.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. pulls $500 million in funding for vaccine development
RFK Jr. pulls $500 million in funding for vaccine development

Yahoo

time18 minutes ago

  • Yahoo

RFK Jr. pulls $500 million in funding for vaccine development

WASHINGTON (AP) — The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed to fight respiratory viruses like COVID-19 and the flu. Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million worth of vaccine development projects, all using mRNA technology, will be halted. The projects — 22 of them — are being led by some of the nation's leading pharmaceutical companies like Pfizer and Moderna to prevent flu, COVID-19 and H5N1 infections. The mRNA vaccines are credited with slowing the 2020 coronavirus pandemic. Kennedy said in the Tuesday statement that he wants the health department to move away from mRNA vaccines, calling on the department to start 'investing in better solutions.' He provided no details on what those technologies might be. Solve the daily Crossword

HS market forecast to reach $7.8bn across 7MM by 2034
HS market forecast to reach $7.8bn across 7MM by 2034

Yahoo

time25 minutes ago

  • Yahoo

HS market forecast to reach $7.8bn across 7MM by 2034

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData. This 15.6% compound annual growth rate (CAGR) is largely attributed to the launch of novel biologics and small molecules targeting multiple inflammatory pathways beyond TNF-alpha inhibition. Currently, only three biologics are approved for HS: AbbVie's Humira (adalimumab), Novartis' Cosentyx (secukinumab), and UCB's Bimzelx (bimekizumab). While Humira, the first approved biologic, remains the market leader, it is widely viewed by KOLs as having limited efficacy, with response rates near 25%–30% and high rates of treatment fatigue. In contrast, the newer IL-17 inhibitors have demonstrated more robust outcomes. In pivotal trials (BE HEARD I/II), Bimzelx achieved hidradenitis suppurativa clinical response (HiSCR) rates of up to 64%, with a faster onset and more durable effect than Cosentyx, despite being a second-line biologic. However, candidiasis risk and high cost may temper uptake. The landscape is now shifting further with a maturing pipeline with varying mechanisms of action. MoonLake Immunotherapeutics' sonelokimab, a tri-specific nanobody targeting IL-17A/F and albumin, is anticipated to be a best-in-class agent based on its deeper tissue penetration and strong Phase II performance. Similarly, Incyte's JAK1 inhibitor povorcitinib is advancing through late-stage development, showing promise particularly in pain reduction and quality-of-life improvement metrics. GlobalData forecasts that by 2034, pipeline products, including sonelokimab and povorcitinib will represent 47.3% of the total HS market. A defining challenge in HS care remains the heterogeneity of disease severity and the high unmet need in both early- and late-stage disease. Diagnostic delays, averaging 7–10 years, often result in irreversible structural damage by the time patients reach speciality care. Furthermore, current treatments target only moderate-to-severe HS, leaving early-stage (Hurley stage I) patients without effective interventions. As highlighted by GlobalData's analysis, products that can safely intervene earlier in disease progression represent a significant commercial opportunity. KOLs also emphasised that clinical endpoints such as HiSCR50 do not fully capture the burden of disease, particularly in tunnel-dominant or refractory cases. As a result, next-generation trials are adopting stricter endpoints such as HiSCR75, and increasingly incorporating patient-reported outcomes such as dermatology life quality index (DLQI) and numerical rating scale-30 (NRS-30). This evolution in trial design aligns with payer and physician expectations for more meaningful, real-world benefits. Market growth will be led by the US, which accounted for over 70% of HS sales in 2024 due to a larger diagnosed population, broader biologic access, and premium pricing. While biosimilar entry may moderate TNF-alpha sales, the expansion of high-cost IL-17 and JAK pathway inhibitors is expected to intensify market competition and drive overall market prices upward due to the premium pricing of these agents. Barriers to market growth include safety monitoring requirements for JAK inhibitors, competition among newer biologics, and access challenges in countries with tighter reimbursement frameworks. However, if emerging therapies show consistent improvements in flare reduction, pain control, and psychosocial burden, as seen with Bimzelx and sonelokimab, they could reshape the treatment algorithm and expand biologic usage to earlier disease stages. With nearly 33 agents in active clinical development and multiple first-in-class mechanisms poised to enter the market, HS is undergoing a therapeutic transformation. GlobalData expects this evolution to redefine the standard of care for a historically underserved patient population. "HS market forecast to reach $7.8bn across 7MM by 2034" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store